GT Biopharma Inc (GTBP)

NASDAQ
2.75
+0.15(+5.77%)
After Hours
2.75
0.00(0.00%)
- Real-time Data
  • Volume:
    138,326
  • Day's Range:
    2.46 - 2.79
  • 52 wk Range:
    1.53 - 9.70

GTBP Overview

Prev. Close
2.6
Day's Range
2.46-2.79
Revenue
-
Open
2.61
52 wk Range
1.53-9.7
EPS
-1
Volume
138,326
Market Cap
83.88M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
183,050
P/E Ratio
-
Beta
0.46
1-Year Change
-74.56%
Shares Outstanding
30,500,717
Next Earnings Date
Nov 09, 2022
What is your sentiment on GT Biopharma?
or
Market is currently closed. Voting is open during market hours.

GT Biopharma Inc Company Profile

GT Biopharma Inc Company Profile

Employees
0

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • Pipeline of this company is terrific, one of the most promising on the board. Average one year target price according to qualified analysts panel is 25 USD (Bloomberg). Market is ignoring all this evidence. To me looks alike a strong buy down here.
    0
    • wait for nasdaq....or phase 1....well
      0
      • Any thought on this
        0